动物实验,肿瘤多药耐药性 z-bo 2020-09-19 357

　　Recently, a reporter from the University of Science and Technology of China found a new "smart" method for the research team of Professor Liang Gaolin of the School of Chemical Science and Professor Zhang Huaming of the School of Life Sciences to overcome the multidrug resistance of tumors. I know that its excellent multi-drug resistance has been confirmed in mice. Tumor multidrug resistance means that tumor cells are not only resistant to a specific chemotherapy drug due to long-term exposure to this chemotherapy drug, but also cross-resistant to other chemotherapy drugs with different structures and functions.

　　This is one of the key reasons leading to the failure of cancer chemotherapy and is the biggest challenge in clinical cancer treatment. The traditional method to solve this problem is to prevent the pumping effect of multidrug resistance or use nanocarriers to load large amounts of drugs. Nanocarriers usually bring harmful and toxic substances into the organism. .. Therefore, it is very important to develop safer anti-multidrug resistance drugs. Liang Gaolin's research team devised a way to "modify" the drug itself. Modified drugs become "smart" and can self-assemble into nano-drugs in cancer cells, with the ability to target concentration and delay drug release. It provides new ideas for the development of anti-multidrug resistance. The "smart" small molecule drug (2-cyanobenzothiazole-paclitaxel) designed by them self-assembles under the action of the fluin enzyme highly expressed in the cell and enters cancer cells to produce paclitaxel-containing nanoparticles. And cancer cells. Nanomedicine slowly releases free paclitaxel through the action of cancer cell esterase to kill cancer cells.

　　We cooperated with Zhang Huafeng's research team to construct a multidrug resistance model for cancer cells and living tumor mice. Compared with the existing paclitaxel, 2-cyanobenzothiazole-paclitaxel is resistant. In cancer cells and mice, the drug index increased by 4.5 times and 1.5 times, respectively, and it was non-toxic to mice. Liang Gaolin said that this new anti-multidrug resistance strategy provides new ideas for safer drug design and cancer treatment, and has great potential in the clinical treatment of cancer.